Document is current
Any future updates will be listed below
-
Authors
Kato, Masaki http://orcid.org/0000-0001-6727-7272
Hori, Hikaru http://orcid.org/0000-0001-8179-3054
Tajika, Aran
- License Information
-
More Information
Article History
Received: 12 November 2022
Revised: 25 February 2023
Accepted: 28 February 2023
First Online: 7 March 2023
Competing interests
: MK has received grant funding from the Ministry of Health, Labor and Welfare of Japan, the Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation, and Japan Research Foundation for Clinical Pharmacology, and speaker’s honoraria from Sumitomo Dainippon Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., GlaxoSmithKline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Lundbeck, and Ono Pharmaceutical. AT received lecture fees from Sumitomo Dainippon Pharma, Eisai, Janssen Pharmaceutical, Meiji-Seika Pharma, Mitsubishi Tanabe Pharma, Otsuka and Takeda Pharmaceutical. HH received speaker honoraria from Eisai, Eli Lilly, Janssen Pharmaceutical, Meiji-Seika Pharma, Otsuka, Pfizer, Sumitomo Dainippon Pharma, and Takeda Pharmaceutical.
